Azeria Therapeutics, a UK-based drug discovery company based on research from University of Cambridge, has attracted £4m ($5.2m) in series A funding from CRT Pioneer Fund, managed by Sixth Element Capital.
CRT Pioneer Fund is a $79.6m fund launched in 2012 by charity Cancer Research UK’s tech transfer arm, Cancer Research Technology, alongside the EU-owned European Investment Fund.
Founded in 2017, Azeria is developing small molecule therapies targeting prostate and hormone resistant cancer based on information from its drug screening…
